PAVM Key Statistics, Chart & Performance
The current stock price of PAVM is 7.29 USD. In the past month the price decreased by -32.31%. In the past year, price decreased by -60.01%.
PAVM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About PAVM
Company Profile
PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2016-07-27. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Company Info
PAVMED INC
360 Madison Avenue, 25th Floor
New York City NEW YORK 10165 US
CEO: Lishan Aklog
Employees: 39
Phone: 12129494319
PAVMED INC / PAVM FAQ
What does PAVM do?
PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2016-07-27. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
What is the stock price of PAVMED INC today?
The current stock price of PAVM is 7.29 USD.
What is the dividend status of PAVMED INC?
PAVM does not pay a dividend.
What is the ChartMill rating of PAVMED INC stock?
PAVM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for PAVMED INC?
PAVMED INC (PAVM) currently has 39 employees.
What is the ownership structure of PAVMED INC (PAVM)?
You can find the ownership structure of PAVMED INC (PAVM) on the Ownership tab.
PAVM Technical Analysis
PAVM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PAVM. PAVM has a bad profitability rating. Also its financial health evaluation is rather negative.
PAVM Financial Highlights
Over the last trailing twelve months PAVM reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 90.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.56% | ||
| ROE | -1.66% | ||
| Debt/Equity | 0.19 |
PAVM Forecast & Estimates
For the next year, analysts expect an EPS growth of 94.12% and a revenue growth -97.58% for PAVM